Novo Nordisk A SNVO
What Novo Nordisk A S does.
Reference is made to the sections '2025 at a glance ' on pag e 7, ' Purpose, strategy and culture' on page 9 and ‘Strategic Aspirations’ on pages 12-34 of our Annual Report 2025.
Novo Nordisk is a global healthcare company and a world leader in Obesity and Diabetes care. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Headquartered in Denmark, Novo Nordisk employs more than 69,500 employees in around 80 countries, and markets its products in approximately 170 countries.
The Company has a broad product portfolio across Obesity and Diabetes care and Rare disease, including a portfolio of glucagon-like-peptide-1 (GLP-1) receptor agonists for the treatment of obesity and diabetes, and modern and human insulins for the treatment of diabetes. During 2025, there has been continued growth across all therapy areas and in many of the geographic areas in which Novo Nordisk operates. However, due to increased competition in both US and ex-US markets, Novo Nordisk has lost volume market share in the GLP-1 market places for both obesity and diabetes.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $126.9B | $140.8B | $177.0B | $232.3B | $290.4B | $309.1B |
| Net income | $42.1B | $47.8B | $55.5B | $83.7B | $101.0B | $102.4B |
| Free cash flow | $46.1B | $48.7B | $66.7B | $83.1B | $73.8B | $59.0B |
More on NVO.
- Novo Nordisk A S summary
- Novo Nordisk A S financial statements
- Novo Nordisk A S key metrics
- Novo Nordisk A S health scores and style box
- Novo Nordisk A S earnings
- Novo Nordisk A S dividends
- Novo Nordisk A S valuation
- Novo Nordisk A S ownership and insiders
- Novo Nordisk A S peers
Figures from Novo Nordisk A S's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.